Probiotic compositions containing clostridiales for inhibiting inflammation

Inventors

Berry, David • Kaplan, Johanne • Rahman, Shaila

Assignees

PharmaBiome AG • Flagship Pioneering Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11612622-B2

Patent

Publication Date

2023-03-28

Expiration Date


Abstract

Pharmaceutical compositions containing microbial entities are described herein. The pharmaceutical compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the pharmaceutical compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.

Core Innovation

The invention relates to probiotic/pharmaceutical compositions and methods of treating autoimmune or inflammatory disease in a subject in need thereof. The method includes administering to the subject a pharmaceutical composition comprising a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia hydrogenotrophica, such that inflammation in the subject is reduced.

The disclosure links immune modulation to cytokine changes, including reductions in pro-inflammatory cytokine secretion and increases in anti-inflammatory cytokine secretion by immune cells. It also describes increasing the proportion of regulatory T cells in the subject.

The described approach is grounded in selecting and screening immunomodulatory bacteria using in vitro host cytokine profiles, immune-cell polarization markers including Treg and Th17, and short-chain fatty acids such as butyrate, acetate, propionate, and valerate. It further presents a bacterial/prebiotic co-culture assay concept to assess host proinflammatory versus anti-inflammatory cytokine responses.

The document also describes treating autoimmune or inflammatory diseases such as GVHD, IBD, ulcerative colitis, Crohn’s disease, multiple sclerosis, systemic lupus erythematosus, type I diabetes, rheumatoid arthritis, Sjögren’s syndrome, uveitis, and Celiac disease, and it discusses gastrointestinal and distal dysbiosis as part of the problem context.

Claims Coverage

The disclosure contains one independent method claim centered on using a single-species bacterial population of Blautia hydrogenotrophica to reduce inflammation, with dependent features that define cytokine-direction effects, immune-cell context, regulatory T cell outcome, and specified disease indications.

Single-species Blautia hydrogenotrophica composition for inflammation reduction

A method of treating autoimmune or inflammatory disease in a subject in need thereof by administering a pharmaceutical composition comprising a bacterial population of a single bacterial species, wherein the single bacterial species is Blautia hydrogenotrophica, such that inflammation in the subject is reduced.

Reduction of pro-inflammatory cytokine secretion

The method further includes administering a pharmaceutical composition to the subject to reduce immune-cell secretion of at least one pro-inflammatory cytokine.

Increase of anti-inflammatory cytokine secretion

The method further includes administering a pharmaceutical composition to the subject to increase secretion of at least one anti-inflammatory cytokine by the subject’s immune cells.

Regulatory T cell proportion increase

The method includes administering the pharmaceutical composition to a subject to increase the proportion of regulatory T cells in the subject.

Autoimmune or inflammatory disease selected from an enumerated group

The method is applied to an autoimmune or inflammatory disease selected from the listed group.

Overall, the claim coverage protects treating autoimmune or inflammatory disease by administering a pharmaceutical composition containing only Blautia hydrogenotrophica so that inflammation is reduced. Dependent claims further define reduced pro-inflammatory cytokine secretion, increased anti-inflammatory cytokine secretion, increased regulatory T cell proportion, and an enumerated set of treatable autoimmune or inflammatory diseases.

Stated Advantages

Inflammation in the subject is reduced.

Reduces immune-cell secretion of at least one pro-inflammatory cytokine.

Increases secretion of at least one anti-inflammatory cytokine by the subject’s immune cells.

Increases the proportion of regulatory T cells in the subject.

Documented Applications

Treating autoimmune or inflammatory disease in a subject in need thereof.

Treating autoimmune or inflammatory diseases selected from an enumerated group, including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, multiple sclerosis (MS), systemic lupus erythematosus (SLE), type I diabetes, rheumatoid arthritis (RA), Sjögren’s syndrome, uveitis, and Celiac disease.

Applications explicitly described include treatment contexts associated with GVHD and IBD, including Crohn’s disease and ulcerative colitis.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.